Rabadi M, Verde M, Camilliere M, Vecchio N, Kandhi S, Sekulic M
Kidney Blood Press Res. 2024; 49(1):1075-1090.
PMID: 39571568
PMC: 11652227.
DOI: 10.1159/000542141.
Yamakoshi S, Nakamura T, Xu L, Kohzuki M, Ito O
Metabolites. 2022; 12(9).
PMID: 36144240
PMC: 9504114.
DOI: 10.3390/metabo12090836.
Qaddumi W, Jose P
Biomedicines. 2021; 9(2).
PMID: 33535566
PMC: 7912729.
DOI: 10.3390/biomedicines9020139.
Pellegrino D, La Russa D, Marrone A
Antioxidants (Basel). 2019; 8(12).
PMID: 31795160
PMC: 6943704.
DOI: 10.3390/antiox8120594.
Reyes-Pardo H, Bautista R, Vargas-Robles H, Rios A, Sanchez D, Escalante B
BMC Nephrol. 2019; 20(1):292.
PMID: 31375080
PMC: 6679465.
DOI: 10.1186/s12882-019-1490-z.
Early onset of renal oxidative stress in small for gestational age newborn pigs.
Soni H, Yakimkova T, Matthews A, Amartey P, Read R, Buddington R
Redox Rep. 2019; 24(1):10-16.
PMID: 30907266
PMC: 6448771.
DOI: 10.1080/13510002.2019.1596429.
Molecular and Cellular Effect of Angiotensin 1-7 on Hypertensive Kidney Disease.
Chen Y, Zhao W, Liu C, Meng W, Zhao T, Bhattacharya S
Am J Hypertens. 2019; 32(5):460-467.
PMID: 30715105
PMC: 6475878.
DOI: 10.1093/ajh/hpz009.
Thick Ascending Limb Sodium Transport in the Pathogenesis of Hypertension.
Gonzalez-Vicente A, Saez F, Monzon C, Asirwatham J, Garvin J
Physiol Rev. 2018; 99(1):235-309.
PMID: 30354966
PMC: 6335098.
DOI: 10.1152/physrev.00055.2017.
Oxidant Mechanisms in Renal Injury and Disease.
Ratliff B, Abdulmahdi W, Pawar R, Wolin M
Antioxid Redox Signal. 2016; 25(3):119-46.
PMID: 26906267
PMC: 4948213.
DOI: 10.1089/ars.2016.6665.
Apocynin Attenuates Cardiac Injury in Type 4 Cardiorenal Syndrome via Suppressing Cardiac Fibroblast Growth Factor-2 With Oxidative Stress Inhibition.
Liu Y, Liu Y, Liu X, Chen J, Zhang K, Huang F
J Am Heart Assoc. 2015; 4(7).
PMID: 26109504
PMC: 4608061.
DOI: 10.1161/JAHA.114.001598.
Angiotensin II-induced hypertension blunts thick ascending limb NO production by reducing NO synthase 3 expression and enhancing threonine 495 phosphorylation.
Ramseyer V, Gonzalez-Vicente A, Carretero O, Garvin J
Am J Physiol Renal Physiol. 2014; 308(2):F149-56.
PMID: 25377910
PMC: 4338926.
DOI: 10.1152/ajprenal.00279.2014.
The angiotensin-(1-7)/Mas axis reduces myonuclear apoptosis during recovery from angiotensin II-induced skeletal muscle atrophy in mice.
Meneses C, Morales M, Abrigo J, Simon F, Brandan E, Cabello-Verrugio C
Pflugers Arch. 2014; 467(9):1975-84.
PMID: 25292283
DOI: 10.1007/s00424-014-1617-9.
Angiotensin II removes kidney resistance conferred by ischemic preconditioning.
Jang H, Kim J, Kim J, Park J, Park K
Biomed Res Int. 2014; 2014:602149.
PMID: 25243156
PMC: 4163347.
DOI: 10.1155/2014/602149.
Expression of the Mas receptor is upregulated in skeletal muscle wasting.
Morales M, Abrigo J, Meneses C, Cisternas F, Simon F, Cabello-Verrugio C
Histochem Cell Biol. 2014; 143(2):131-41.
PMID: 25208653
DOI: 10.1007/s00418-014-1275-1.
Exogenous administration of thiosulfate, a donor of hydrogen sulfide, attenuates angiotensin II-induced hypertensive heart disease in rats.
Snijder P, Frenay A, de Boer R, Pasch A, Hillebrands J, Leuvenink H
Br J Pharmacol. 2014; 172(6):1494-504.
PMID: 24962324
PMC: 4369259.
DOI: 10.1111/bph.12825.
ACE2 deficiency increases NADPH-mediated oxidative stress in the kidney.
Wysocki J, Ortiz-Melo D, Mattocks N, Xu K, Prescott J, Evora K
Physiol Rep. 2014; 2(3):e00264.
PMID: 24760518
PMC: 4002244.
DOI: 10.1002/phy2.264.
Loss of menin mediated by endothelial cells treated with CoPP is associated with increased maturation of adipocytes.
Angevine K, Wuescher L, Mensah-Osman E
Adipocyte. 2013; 2(4):207-16.
PMID: 24052896
PMC: 3774696.
DOI: 10.4161/adip.24722.
Fulvene-5 inhibition of Nadph oxidases attenuates activation of epithelial sodium channels in A6 distal nephron cells.
Trac D, Liu B, Pao A, Thomas S, Park M, Downs C
Am J Physiol Renal Physiol. 2013; 305(7):F995-F1005.
PMID: 23863470
PMC: 3798745.
DOI: 10.1152/ajprenal.00098.2013.
Determinants of kidney oxygen consumption and their relationship to tissue oxygen tension in diabetes and hypertension.
Hansell P, Welch W, Blantz R, Palm F
Clin Exp Pharmacol Physiol. 2012; 40(2):123-37.
PMID: 23181475
PMC: 3951849.
DOI: 10.1111/1440-1681.12034.
L/N-type calcium channel blocker cilnidipine reduces plasma aldosterone, albuminuria, and urinary liver-type fatty acid binding protein in patients with chronic kidney disease.
Abe M, Maruyama N, Suzuki H, Inoshita A, Yoshida Y, Okada K
Heart Vessels. 2012; 28(4):480-9.
PMID: 22914905
DOI: 10.1007/s00380-012-0274-1.